Stock Comparison

LLY vs NVO

Eli Lilly and Co vs Novo Nordisk A/S

The Verdict

NVO takes this one.

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Winner

NVO

Novo Nordisk A/S

1.3

out of 10

Distressed

Head-to-Head

$965.0B

Market Cap

$1.3T

52.6

P/E Ratio

10.6

N/A

Profit Margin

37.2%

N/A

Return on Equity

66.4%

N/A

Debt-to-Equity

0.7

Moderate

Overall Risk

Moderate

0.5

DVR Score

1.3

The Deep Dive

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

NVO1.3/10

Novo Nordisk (NVO) is a pharmaceutical powerhouse, commanding leadership in the diabetes and obesity markets, fueled by its dominant GLP-1 franchise. The Q1 2026 results show strong reported sales growth of 32% YoY at CER, and the company raised its 2026 outlook, reflecting robust demand. However, a critical red flag for 10x growth potential is the explicit *4% decline in adjusted sales due to low...

Full NVO Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.